Nordicus Partners Corporation Reports Financial Results with Continued Net Loss and Strategic Acquisitions

Nordicus Partners Corporation reported its financial results for the three and nine months ended December 31, 2025, revealing a continued focus on its strategic acquisitions and operational developments in the life sciences sector. The company did not generate any revenue during the reported periods, maintaining a net loss of $1.2 million for the three months and approximately $3.9 million for the nine months, compared to losses of $1.5 million and $2.3 million in the respective periods of the previous year. The net loss per share attributable to Nordicus was $(0.07) for the three months and $(0.22) for the nine months, reflecting a decrease in losses per share compared to $(0.13) and $(0.35) in the prior year.

In terms of operational changes, Nordicus has made significant strides in its portfolio, which now includes three preclinical biotechnology companies: Orocidin, Bio-Convert, and NoviThera. The company has focused on enhancing its research and development capabilities, with total operating expenses for the three months amounting to $1.1 million, a decrease from $1.3 million in the prior year. Notably, officer compensation expenses decreased by 75% to $128,022, while professional fees increased by 53% to $242,603, reflecting ongoing advisory services related to business development.

The company’s balance sheet as of December 31, 2025, showed total assets of $75.9 million, up from $70.2 million at the end of the previous fiscal period. This increase was primarily driven by a rise in in-process research and development assets, which grew to $46.4 million from $42.7 million. Goodwill also increased to $27.7 million, reflecting the company’s acquisitions. The total stockholders' equity rose to $64.8 million, compared to $59.9 million in the prior period, indicating a strengthening financial position.

Nordicus has also been active in its capital management strategies, having authorized a share repurchase program allowing for the buyback of up to 200,000 shares. The company repurchased 57,642 shares at $1.36 each during the period. Furthermore, Nordicus raised approximately $3.9 million through the issuance of common stock, which is expected to support its operational and strategic initiatives moving forward. The company is also exploring opportunities for uplisting to the Nasdaq Capital Market, which could enhance its capital-raising capabilities.

Looking ahead, Nordicus aims to leverage its acquisitions and ongoing research to drive future growth. The company is focused on advancing its portfolio companies through critical clinical milestones, with Orocidin and Bio-Convert making progress in their respective drug development programs. However, the company acknowledges the challenges ahead, including the need for additional financing to support its operations and the uncertainty surrounding the commercialization of its products. Management remains committed to navigating these challenges while pursuing its mission to support Nordic life sciences companies in the U.S. market.